TMPRSS2 and neoplasm: The patient with advanced castration-resistant prostate cancer with neuroendocrine differentiation was a 53-year-old man with a tumour harbouring duplication of exons 1–3 in ATR, as well as BRCA2 and TMPRSS2-ERG somatic tumour mutations.